Despite formidable barriers, several tumor-associated antigens—such as mesothelin (MSLN), prostate stem cell antigen (PSCA), carcinoembryonic antigen (CEA), HER2, MUC1, and CD133—are being explored as targets [84]. This evidence concerns the gene CEACAM5 and neoplasm.